The City With the highest HIV/AIDS Rates in the US

HIV Incidence and Prevalence in the United States

The government of the United States has set a goal to reduce the number of HIV infections by 75% by 2025 and 90% by 2030 as part of its Ending the HIV Epidemic in the US initiative. According to the Centers for Disease Control (CDC), there were approximately 32,100 estimated new infections in 2021 by transmission category in the US. Of these new infections 70% were reported among gay, bisexual, and male-to-male sexual contact, 22% were reported to be transmitted by heterosexual contact, and around 8% were transmitted among people who inject drugs. As per the Ending the HIV Epidemic Initiative, the government aims to curb the new infection number to 9,000 new infections by 2025, and to 3,000 by 2030.

In a regional analysis of the HIV incidence and prevalence within the United States, South America accounted for approximately 52% of the new HIV infections, followed by the Western and Mid-Western regions with 21% and 14% new infections during 2021. Northeast America accounted for the least new infections and reported only a 14% new infection rate during the same year. Analyzing the diagnosis trends among different races and ethnicities within America reveals that during 2021, 36% of African American gay or bisexual men were diagnosed with HIV infection, followed by Hispanic/Latino and white Americans with 33% and 25% diagnosis rates during 2021. Although the overall HIV diagnosis shows improvement as compared to 2017 figures, with HIV diagnosis among men and women going down by 15% and 11% respectively from 2017 to 2021. However, the government still needs to go a long way in reaching its 2025 target as according to the AtlasPlus data by CDC, around 37,601 people were diagnosed with HIV in 2022, up by 5.41% as compared to 2021 diagnosis figures.

An Overview of the Global HIV Drug Market

According to a report by Fortune Business Insights, the global HIV drug market was valued at $34.13 billion in 2023. The market is forecasted to grow at a compound annual growth rate of 6.2% to reach $58.24 billion by 2032. The viral infection is spreading around the world at a growing rate. According to the World Health Organization, an estimated 39.0 million people were living with the infection in 2022. However, on the bright side, the number of incidence of new HIV cases has reduced since 2010. As per the data, approximately 1.3 million people acquired HIV in 2022 as compared to 2.1 million people acquiring the virus in 2010. The increased awareness of the virus, prompt diagnosis, and demand for treatment medication are factors contributing to growth in the market.

Some of the leading pharmaceutical companies contributing to curbing and treating HIV infection include GSK plc (NYSE:GSK) and Merck & Co., Inc. (NYSE:MRK).

GSK plc (NYSE:GSK) is a leading pharmaceutical company based in the United Kingdom that researches and develops vaccines and other general medicines. The company through its subsidiaries operates in the United Kingdom, the United States, and internationally. On March 5 Reuters reported that GSK plc’s (NYSE:GSK) new HIV drug formula could support longer dosing intervals. The new formula can be potentially administered at least every 4 months as opposed to the previous requirement of 2-month dosing intervals. Moreover, the company has shifted its focus to long-acting treatments and prevention therapies.

Merck & Co., Inc. (NYSE:MRK) is another international healthcare company that operates through two segments; pharmaceuticals and animal health. On March 6, Merck & Co., Inc. (NYSE:MRK) along with Gilead Sciences, Inc. (NASDAQ:GILD) announced the results of a phase 2 clinical trial showing an oral once-weekly combination of the Regimen of Islatravir and Lenacapavir as a viable option to suppress the viral HIV infection. The combination was found to maintain a high rate (94.2%) of viral suppression rate. Gilead Sciences, Inc. (NASDAQ:GILD) is a leading innovator in developing treatment and conducting cure research for HIV.

The City With the highest HIV/AIDS Rates in the US

1. Fort Lauderdale-Pompano Beach-Sunrise, Florida

Average Rate of HIV and AIDS per 100,000: 929.3%

AIDS Rate per 100,000: 614%

HIV Rate per 100,000: 1244.6%

HIV Cases: 20,733

AIDS Cases: 10,228

The Fort Lauderdale-Pompano Beach-Sunrise Metropolitan Statistical Area in the state of Florida ranks as the city with the highest HIV/AIDS rates in the US. The area consists of Fort Lauderdale, Pompano Beach, and Sunrise cities which are located close to each other. The area had a combined average rate of HIV and AIDS prevalence of 929.3% per 100,000 people in 2022.

In addition, there were approximately 20,733 HIV cases and 10,228 AIDS cases in the area in 2022. All three major cities in the metro area are famous for their beaches and nightlife.

Copyright: Dive into this article, curated with care by SDG Investors Inc. Our advanced AI technology searches through vast amounts of data to spotlight how we are all moving forward with the Sustainable Development Goals. While we own the rights to this content, we invite you to share it to help spread knowledge and spark action on the SDGs.

Fuente: finance.yahoo.com

Join us, as fellow seekers of change, on a transformative journey at https://sdgtalks.ai/welcome, where you can become a member and actively contribute to shaping a brighter future.